WithdrawnPhase 2

Sphenopalatine Ganglion Block for the Treatment of Post-Stroke Headache

Stopped: Due to COVID-19 and both co-investigators have departed from the institution, we weren't able to enroll participants. Additionally, funding has lapse

United States0Started 2022-03-23

Plain-language summary

Determine the effects of sphenopalatine ganglion (SPG) block in post-stroke headache.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. 18 years or older;
✓. hospitalization at the University of Utah Hospital with a diagnosis of acute ischemic or hemorrhagic stroke; confirmed acute post-stroke headache by treating physician;
✓. meets at least one of the following International Classification of Headache Disorder-3 (ICHD-3) criteria: 6.1.1.1 (Acute Headache Attributed to Ischemic Stroke), 6.2.1 (Headache attributed to non-traumatic intracerebral hemorrhage), 6.2.2 (Acute headache attributed to non-traumatic subarachnoid hemorrhage); received at least one medication for headache during hospitalization.

Exclusion criteria

✕. Previous treatment with SPG Block for post-stroke headache
✕. history of prophylactic medication use for headache or migraine;
✕. pregnant at time of stroke

What they're measuring

Change in Number of Migraine Headaches During Treatment Phase

Timeframe: 90 days

Trial details

NCT IDNCT05365880

SponsorUniversity of Utah

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-03-22

View on ClinicalTrials.gov More Headache trials